BriaCell Therapeutics

TSX:BCT
BCTX
Request Investor Info

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is a clinical-stage small-cap biotech immunotherapy company advancing novel approaches to fight cancer and improve patients’ lives. Focused initially on breast cancer immunotherapy, BriaCell is developing innovative off-the-shelf immunotherapy platforms with the potential to transform outcomes for patients with cancer.

‍

Projects
Stories
Presentation
Contact
Management
Financials
BriaCell Therapeutics Stock Price Today
BriaCell Therapeutics Fundamental Data by TradingView

Company Feed

BriaCell: Advancing Toward Approval with Late-Stage Breast Cancer Immunotherapy
December 18, 2025

BriaCell: Advancing Toward Approval with Late-Stage Breast Cancer Immunotherapy

BriaCell Therapeutics is in the final stages of clinical testing for its innovative immunotherapy in metastatic breast cancer, offering a new treatment path for patients with limited options.

This is some text inside of a div block.
Subscribe and receive the investor Info